ANTX   $1.29  21.70% Market Closed After Close 1.28 -0.78%

AN2 Therapeutics Inc
Last Events:

2023-08-09 Signal in Stochastic changed from bearish weakening to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

2023-08-09 Signal in MACD changed from bullish weakening to bullish recovery. Oscillator MACD is in the positive territory it crossed the signal line from the bottom and grows. These factors mean that the market confirms the tendency to growth. Last signal: main and signal line crossing.

2023-08-09 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-09 Signal in EMA100 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-08-06 Signal in Stochastic changed from bearish to bearish weakening. The stochastic indicator is in the lower part of the neutral territory and it grows. These factors indicate that the upside trend is confirmed. Last signal: main and signal line crossing.

2023-08-06 Signal in MACD changed from bullish recovery to bullish weakening. Oscillator MACD is in the positive territory it's lower than the signal line and falls. These factors mean that the growing period is over. Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: exit from the overbought zone.

2023-08-06 Trend Power changed from to almost flat.


Current temperature: 3.69
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 3
Target Price Mean 10.33
Mean unverified/preliminary 10.33 / 10.33
Target Price Low / High 1.00 / 25.00
Median / STD DEV 5.00 / 12.86
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy None ActivelyBuy
rsi ActivelyBuy ActivelyBuy None
macd ActivelyBuy None None
stoch ActivelyBuy None None
ma20 Sell None None
ma50 ActivelyBuy None None
ma100 Buy None ActivelyBuy
Candlestick PatternNov. 18, 2024 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US0373261058
ceo Mr. Eric E. Easom
Website https://www.an2therapeutics.com
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.